Cognition Therapeutics, Inc. develops small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Their lead product candidate, CT1812, is currently in Phase II clinical trials for Alzheimer's disease, DLB, and AMD. The company also has two other products under development for synucleinopathies, Parkinson's disease, and dry AMD.